NASDAQ:UNCY

Unicycive Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy UNCY

*Your capital is at risk

$7.87

+1.02 (+14.89%)

At Close: Jun 22, 2026

Unicycive Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.60. In total, the insiders bought 161.89M and sold 2.93M UNCY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.60
● Buy	161.89M shares
● Sell	2.93M shares
92% Buy Activity Weak Positive Correlation
Buy Signal High Confidence May 14, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.6. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	115 275 Value: $85.3K
Jul 11, 2023 Buy	Warrant (right to buy M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	79 252 Value: $42.8K
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	72 047 Value: $42.5K
Jul 11, 2023 Buy	Series A-1 Convertible Preferred Stock M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	50 Value: $25
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	46 110 Value: $34.1K
Jul 11, 2023 Buy	Common Stock M-Exempt	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	41 845 Value: $20.5K
Jul 11, 2023 Buy	Warrant (right to buy M-Exempt	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	31 700 Value: $17.1K
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	28 818 Value: $17.0K
Jul 11, 2023 Buy	Series A-1 Convertible Preferred Stock M-Exempt	Gupta Pramod EVP, Pharmaceuticals And Bd	Officer	20 Value: $10
Jul 11, 2023 Buy	Common Stock M-Exempt	Gupta Shalabh K. CEO	CEO / President	104 612 Value: $51.3K
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Gupta Shalabh K. CEO	CEO / President	115 275 Value: $85.3K
Jul 11, 2023 Buy	Warrant (right to buy M-Exempt	Gupta Shalabh K. CEO	CEO / President	79 252 Value: $42.8K
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Gupta Shalabh K. CEO	CEO / President	72 047 Value: $42.5K
Jul 11, 2023 Buy	Series A-1 Convertible Preferred Stock M-Exempt	Gupta Shalabh K. CEO	CEO / President	50 Value: $25
Jul 11, 2023 Buy	Tranche C Warrants (right to buy) C-Conversion	Aggarwal Gaurav Director	Director	18 621 655 Value: $13.8M
Jul 11, 2023 Buy	Series A-2 Preferred Stock C-Conversion	Aggarwal Gaurav Director	Director	13 429 000 Value: $0
Jul 11, 2023 Buy	Tranche A Warrants (right to buy) C-Conversion	Aggarwal Gaurav Director	Director	12 802 388 Value: $6.90M
Jul 11, 2023 Buy	Tranche B Warrants (right to buy) C-Conversion	Aggarwal Gaurav Director	Director	11 638 534 Value: $6.90M
Jul 11, 2023 Buy	Common Stock C-Conversion	Aggarwal Gaurav Director	Director	3 470 152 Value: $0
Jul 11, 2023 Sell	Series A-1 Preferred Stock C-Conversion	Aggarwal Gaurav Director	Director	8 077 Value: $4K
Jul 11, 2023 Buy	Common Stock M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	104 612 Value: $51.3K
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	115 275 Value: $85.3K
Jul 11, 2023 Buy	Warrant (right to buy M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	79 252 Value: $42.8K
Jul 11, 2023 Buy	Warrant (right to buy) M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	72 047 Value: $42.5K
Jul 11, 2023 Buy	Series A-1 Convertible Preferred Stock M-Exempt	Jermasek Douglas EVP Of Corporate Strategy	Officer	50 Value: $25

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT UNICYCIVE THERAPEUTICS, INC.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California....

Read Full Profile Here